Cue Health Leadership

Clint Sever is co-founder and Chief Product Officer of Cue Health, a health technology company whose mission is to enable personalized, proactive, and informed healthcare that empowers people to live their healthiest lives.

Clint leads product development and product design strategy at Cue, including the look and feel of Cue products, user interface, and packaging. Clint has overseen hardware engineering, supply chain development, and scaled manufacturing of Cue consumable cartridges, cartridge readers, and accessories. He is also responsible for the design and engineering of the facilities in which Cue products are made.

The idea for Cue was conceived in 2010 when Clint and co-founder & Cue CEO Ayub Khattak recognized the problems with how the current health structure collects, communicates, and uses health data. They saw the opportunity to create a new model for care and started Cue to create tools that empower healthcare providers and consumers by increasing their access to actionable health data.

Clint received a Bachelor of Science degree in retail and consumer science from the University of Arizona.

Chris is an American Healthcare Executive and Entrepreneur. As Founder and CEO of Genzum Life Sciences, Chris established product development and licensing strategies, scaling the company from early stage R&D company to FDA approval. Today the Genzum has a pipeline of FDA targeted products and licensing partnerships with leading multibillion dollar pharmaceutical companies. In 2017, Chris co-led Cue Health's Series B financing and joined as a Board Member & Operating Partner working closely with Cue's founders. Chris helps lead Cue's efforts with U.S. Health and Human Services, U.S. Department of Defense and State and Local Governments as well as strategic partnerships with Mayo Clinic, the NBA and Henry Schein Medical.

Chris is a successful early stage healthcare investor through Synergy Ventures. Synergy's investments to date include Innopharma (sold to Pfizer), TesoRx (Ph I, Ph II), Ocugen Pharma(IPO), ImagenBio, Cytecare Cancer Hospitals, Second Sight(IPO), PulseBiosciences(IPO), Endra Life Sciences(IPO), AquaMetals, Sonosim, Imprimis Pharmaceuticals, CueBioPharma(IPO), ProventionBio(IPO), Eton Pharma(IPO) and Cue Health.

Chris is an active member of YPO and on the boards of the Milken Institute Global YLC Los Angeles, Network for Teaching Entrepreneurship (NFTE) and Cue Health. He is an alumni of California State University and Pepperdine University School of Business.

John Gallagher is Chief Financial Officer of Cue Health, a healthcare technology company. At Cue, John is responsible for all the company’s internal and external facing financial functions, including financial planning and analysis, treasury, investor relations, accounting, tax, and audit.

John joined Cue from a multinational medical technology company, Becton, Dickinson & Co. (BD), where he served as CFO of its Medical Segment and Treasurer. Upon joining BD in 2012, he was named Corporate Treasurer, a role he held throughout his tenure at the company. John also had responsibility for corporate finance, including financial planning and analysis, and was Controller and Chief Accounting Officer during two acquisitions for the company.

Prior to BD, John served as Vice President, Financial Planning & Analysis at NBC Universal. He also served as Assistant Controller of Corporate Treasury for General Electric Company. John began his career with Ford Motor Company, holding various roles across Treasury, Internal Audit, and Product Development Finance.

John holds a Bachelor of Science degree in finance from Clemson University and received his Master of Business Administration degree from the University of Pittsburgh.

David Arida is Chief Operating Officer of Cue Health, a health technology company whose mission is to enable personalized, proactive, and informed healthcare that empowers people to live their healthiest lives.

As COO, David will oversee Cue Health’s worldwide supply chain, manufacturing operations, and expansion of its product line, positioning the Company for continued growth.

Prior to joining Cue Health, David served for a decade in multiple senior operational roles at Dexcom, a diabetes care technology company. He was most recently Dexcom’s senior vice president of global manufacturing operations. Before Dexcom, David held a number of management, consulting, and engineering positions at Alere (now Abbott), Amylin Pharmaceuticals (now AstraZeneca), and PRTM (now PWC).

David holds an MBA and a Masters in Engineering Management from Northwestern University as well as a Bachelor of Science in Chemical Engineering from Cornell.

Clint Sever is co-founder and Chief Product Officer of Cue Health, a health technology company whose mission is to enable personalized, proactive, and informed healthcare that empowers people to live their healthiest lives.

Clint leads product development and product design strategy at Cue, including the look and feel of Cue products, user interface, and packaging. Clint has overseen hardware engineering, supply chain development, and scaled manufacturing of Cue consumable cartridges, cartridge readers, and accessories. He is also responsible for the design and engineering of the facilities in which Cue products are made.

The idea for Cue was conceived in 2010 when Clint and co-founder & Cue CEO Ayub Khattak recognized the problems with how the current health structure collects, communicates, and uses health data. They saw the opportunity to create a new model for care and started Cue to create tools that empower healthcare providers and consumers by increasing their access to actionable health data.

Clint received a Bachelor of Science degree in retail and consumer science from the University of Arizona.

Chris is an American Healthcare Executive and Entrepreneur. As Founder and CEO of Genzum Life Sciences, Chris established product development and licensing strategies, scaling the company from early stage R&D company to FDA approval. Today the Genzum has a pipeline of FDA targeted products and licensing partnerships with leading multibillion dollar pharmaceutical companies. In 2017, Chris co-led Cue Health's Series B financing and joined as a Board Member & Operating Partner working closely with Cue's founders. Chris helps lead Cue's efforts with U.S. Health and Human Services, U.S. Department of Defense and State and Local Governments as well as strategic partnerships with Mayo Clinic, the NBA and Henry Schein Medical.

Chris is a successful early stage healthcare investor through Synergy Ventures. Synergy's investments to date include Innopharma (sold to Pfizer), TesoRx (Ph I, Ph II), Ocugen Pharma(IPO), ImagenBio, Cytecare Cancer Hospitals, Second Sight(IPO), PulseBiosciences(IPO), Endra Life Sciences(IPO), AquaMetals, Sonosim, Imprimis Pharmaceuticals, CueBioPharma(IPO), ProventionBio(IPO), Eton Pharma(IPO) and Cue Health.

Chris is an active member of YPO and on the boards of the Milken Institute Global YLC Los Angeles, Network for Teaching Entrepreneurship (NFTE) and Cue Health. He is an alumni of California State University and Pepperdine University School of Business.